Given the ongoing extensive research on prostate cancer–associated membrane proteins such as Prostate Specific Membrane Antigen (PSMA), these strategies have strong potential to be translated into therapies for inhibiting prostate cancer metastasis, supported by in vitro, in vivo, and clinical observations [112,113,114]. This evidence concerns the gene FOLH1 and prostate carcinoma.